Argentiere Capital’s Pfizer PFE Stock Holding History

Argentiere Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-88,536	Closed	-$3.7M	–	93
2018 Q3	$3.7M	Buy	+88,536	New	+$3.41M	0.38%	48
2016 Q4	–	Sell	-210,800	Closed	-$399K	–	74
2016 Q3	$399K	Buy	+210,800	New	+$7.05M	0.38%	37
2016 Q2	–	Sell	-737,800	Closed	-$238K	–	81
2016 Q1	$238K	Buy	+737,800	New	+$21.1M	0.14%	61

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Argentiere Capital's PFE Position: Q1 2017 in Review

Argentiere Capital sold out of Pfizer (PFE) in Q1 2017, closing a stake of 68,510 shares — an estimated $2.11M sold.

Argentiere Capital first reported a position in PFE in Q1 2015 and held it in 8 quarters. The position peaked at $9.1M in Q1 2016. 2,075 funds tracked by Wall St. Rank hold PFE as of Q1 2017.

Argentiere Capital reported no remaining Pfizer position as of Q1 2017 after selling out during the quarter.
Argentiere Capital sold 68,510 Pfizer shares in Q1 2017, an estimated $2.11M.
Argentiere Capital first reported a position in Pfizer in Q1 2015 and held it in 8 quarters.
Argentiere Capital's Pfizer position peaked at $9.1M in Q1 2016.
2,075 funds tracked by Wall St. Rank held Pfizer as of Q1 2017.

Based on Argentiere Capital's 13F filing for Q1 2017, filed 15 May 2017.